Last reviewed · How we verify

Clostridium Endometritis — Treatment Landscape & Competitive Intelligence

Clostridium Endometritis (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Clostridium Endometritis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Claforan CEFOTAXIME Sterimax Cephalosporin Antibacterial 1981-01-01
Metro I.V. In Plastic Container METRONIDAZOLE Baxter Nitroimidazole Antimicrobial [EPC] 1963-01-01
Metronidazol Metronidazol University of Oslo Thioredoxin reductase

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 1 drug in Clostridium Endometritis
  2. Baxter · 1 drug in Clostridium Endometritis
  3. Sterimax · 1 drug in Clostridium Endometritis
  4. University of Oslo · 1 drug in Clostridium Endometritis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Clostridium Endometritis:

Cite this brief

Drug Landscape (2026). Clostridium Endometritis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/clostridium-endometritis. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing